Urine RNA Test Detects Bladder Cancer with 95% Sensitivity and Predicts Treatment Response
A Stanford liquid biopsy using urine cell-free RNA detects localized bladder cancer with 95% sensitivity and predicts who will respond to BCG therapy.
Summary
Stanford researchers developed uRARE-seq, a liquid biopsy method that analyzes cell-free RNA fragments shed into urine. Testing 683 urine samples from cancer patients and controls, the method detected localized bladder cancer with 95% sensitivity at 90% specificity — outperforming urine tumor DNA analysis. Beyond detection, the test identified minimal residual disease and distinguished complete molecular responses after surgery from those after intravesical BCG. Crucially, it predicted treatment response before therapy began: patients who responded to BCG had preexisting immune signatures in their urine, while non-responders showed higher expression of proliferation genes. A pretreatment biomarker achieved an AUC of 0.93 for predicting BCG versus chemotherapy response across 114 patients and was strongly associated with recurrence risk. The approach may extend to other urologic cancers.
Detailed Summary
Bladder cancer is one of the most common malignancies worldwide, and its management depends heavily on repeated invasive cystoscopies for detection and monitoring. A non-invasive, molecularly precise alternative has long been sought — and this study from Stanford University represents a major step in that direction.
Researchers developed uRARE-seq (urine random priming and affinity capture of cell-free RNA for enrichment analysis by sequencing), a method that captures and sequences cell-free RNA fragments shed into urine. They applied it to 683 urine samples from patients with prostate, kidney, or bladder cancer and from healthy controls, demonstrating that urine cfRNA reflects gene expression from genitourinary tissues and, in cancer patients, from tumors themselves.
For bladder cancer detection specifically, uRARE-seq achieved 95% sensitivity at 90% specificity, outperforming urine circulating tumor DNA analysis and remaining unaffected by field-effect mutations — genetic alterations in surrounding non-tumor tissue that can confound DNA-based tests. The method also sensitively detected minimal residual disease and distinguished complete molecular responses after surgery from those after intravesical BCG immunotherapy.
Perhaps most clinically striking, pretreatment urine samples revealed biological differences that predicted treatment outcomes. BCG responders showed enrichment for T cell and other immune signatures in their pretreatment urine, suggesting a preexisting antitumor immune environment. Non-responders exhibited elevated expression of proliferation-related genes. A biomarker model built from these signatures predicted likelihood of response to BCG versus chemotherapy with an AUC of 0.93 across 114 patients and was strongly associated with risk of recurrence.
Prospective validation is needed before clinical adoption. Nonetheless, uRARE-seq offers a compelling noninvasive platform for bladder cancer detection, treatment selection, and monitoring.
Key Findings
- uRARE-seq detected localized bladder cancer with 95% sensitivity at 90% specificity, outperforming urine tumor DNA methods.
- The urine RNA test identified minimal residual disease and distinguished complete molecular responses after surgery from those after intravesical BCG.
- Pretreatment urine from BCG responders showed enriched T cell and immune gene signatures, suggesting a preexisting antitumor immune response.
- A pretreatment biomarker predicted likelihood of BCG versus chemotherapy response with an AUC of 0.93 across 114 patients and was strongly associated with recurrence risk.
- Non-responders to BCG showed elevated expression of proliferation-related genes in pretreatment urine.
Methodology
The study analyzed 683 urine samples from patients with prostate, kidney, or bladder cancer and controls using uRARE-seq, a novel sequencing method enriching urine cell-free RNA fragments via random priming and affinity capture. Treatment response prediction was evaluated in a cohort of 114 pretreatment urine samples. The design appears retrospective; the abstract does not specify whether all cohorts were independent validation sets.
Study Limitations
The authors explicitly note that prospective studies are needed to confirm clinical utility. Cohort composition and whether validation cohorts were fully independent are not clear from the abstract. Several authors report competing interests including equity stakes in Resero Bio, a company commercializing related technology, and patent filings related to urine cfRNA.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: